We are pursuing a precision medicine approach to develop a broad range of therapeutics for neurodegenerative diseases
Our strategy is to develop a pipeline of therapeutic candidates, that we believe will activate and restore microglial function. We believe that each therapeutic candidate in our pipeline has the potential to be developed for multiple neurodegenerative diseases. Our precision medicine approach begins with rare, genetically defined diseases for which microglial dysfunction is believed to be a key driver of disease pathology and then utilizes findings from these efforts to inform expansion into larger and more common neurodegenerative diseases.
Our first therapeutic candidates are designed to activate TREM2, a key microglial receptor protein that mediates responses to environmental signals in order to maintain brain health and whose dysfunction is linked to neurodegeneration. We have two clinical programs that are designed to target TREM2.
